Pharmacokinetic comparison of three delivery systems for subcutaneous testosterone administration in female mice

• Published in: General and comparative endocrinology 2022-10, Vol.327, p.114090-114090, Article 114090
• Main Authors: Hashim, Prianka H., Kinnear, Hadrian M., Cruz, Cynthia Dela, Padmanabhan, Vasantha, Moravek, Molly B., Shikanov, Ariella
• Format: Article
• Language: English
• Subjects: Administration; Animals; Drug Implants; Estrous cycle; Female; Heptanoates; Injections, Subcutaneous; Mice; Mice, Inbred C57BL; Pharmacokinetics; Reversibility; Subcutaneous implants; Testosterone
• ISSN: 0016-6480; 1095-6840
• DOI: 10.1016/j.ygcen.2022.114090

•Compared the release dynamics of three different delivery methods of subcutaneous testosterone administration.•The body’s overall exposure to T seems similar across administration methods for T enanthate.•Pellets and silastic tubing allow for quick return to baseline T levels and regular estrous cyclicity.•Silastic implants can be used for long-term elevation in T levels. Transmasculine individuals are often prescribed testosterone (T) for masculinizing hormone therapy. Mouse models mimicking transmasculine T therapy require reliable long-term T administration. The objectives of this study were three-fold, namely, to compare: 1) the release dynamics of three different subcutaneous delivery systems of T enanthate administration (subcutaneous injections, commercially available pellets, and silastic implants) over a 6-week period in postpubertal C57BL/6N mice, 2) to compare the timing for T levels in plasma to return to baseline and cyclicity to resume after cessation of T between injections and pellets, 3) to utilize silastic implants to achieve sustainable increase in T levels utilizing T enanthate and crystalline T. All three modes of T administration resulted in an increase in T levels in plasma. Pharmacokinetic analyses showed a similar overall exposure to T enanthate over 6 weeks (integrated area) for, subcutaneous injection (0.45 mg two times per week and 0.90 mg one time per week), pellet (5 mg 60-day release), and silastic implant (5 mg 21 week) groups. Crystalline T had lower solubility and a decreased integrated area compared to T enanthate, even when implanted at a higher dosage, indicating different pharmacokinetic profiles based on type of T formulation when utilizing the same silastic delivery method. Surgical removal of pellets and silastic tubing led to a quick drop in T levels and resumption of estrous cyclicity, while cessation of injections required a long washout period for T levels to drop and estrous cycles to resume. Sustained elevation in T levels was achieved for at least 21 weeks with silastic implants. As all three delivery methods are able to elevate T levels in female mice for at least 6 weeks, choice of T administration method should be based on outcomes of interest and study design.